First-and second-line treatment options for colorectal cancer mainly include fluorouracil-based chemotherapy in combination with oxaliplatin and irinotecan, as well as treatments targeting vascular endothelial growth factor (VEGF) (mainly using bevacizumab) or epidermal growth factor receptor (EGFR) (the latter is primarily indicated for RAS wild-type tumors) (7). The gene discussed is EGFR; the disease is colorectal cancer.